Ionis secures FDA approval for zilganersen, its first solo neurology therapy for Alexander disease

Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration has granted approval to its investigational RNA‑based drug zilganersen for the treatment of Alexander disease, a rare neurodegenerative condition affecting children.

The approval marks Ionis’s first fully owned neurology product, expanding its pipeline beyond antisense therapies that have been partnered with other companies. Zilganersen works by targeting the underlying genetic cause of the disease.

The decision opens a pathway for Ionis to commercialize the therapy in the United States and potentially pursue additional indications or global submissions. The company said it will begin manufacturing and distribution preparations.

Analysts noted that the clearance could boost Ionis’s revenue outlook, given the unmet medical need in this orphan disease area, though the market size remains limited.